Literature DB >> 9435681

Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure.

N D Vaziri1, X Q Wang, K Liang.   

Abstract

In a recent study, we found marked downregulation of lipoprotein lipase (LPL) gene expression in fat, myocardium, and skeletal muscle of rats with chronic renal failure (CRF). Recently, hepatic lipase expression was shown to be depressed in CRF rats, and parathyroidectomy (PTX) was shown to reverse this abnormality. This study was undertaken to determine whether down-regulation of LPL expression in CRF is due to secondary hyperparathyroidism. Accordingly, LPL mRNA (Northern analysis), protein mass (Western analysis using mouse antibovine LPL monoclonal antibody, 5D2), and catalytic activity of the fat pad and soleus muscle were compared in five-sixths-nephrectomized male rats (CRF), parathyroidectomized CRF rats, and sham-operated control animals. The CRF animals exhibited marked hypertriglyceridemia and significant reductions of fat and skeletal muscle LPL mRNA abundance, protein mass, and catalytic activity (P < 0.05 vs. controls, for all parameters). PTX completely normalized the LPL mRNA, protein mass, and enzymatic activity and partially ameliorated the CRF hypertriglyceridemia (P < 0.05 vs. CRF group, for all parameters). Thus secondary hyperparathyroidism is responsible for impaired LPL expression in experimental CRF. This abnormality is completely corrected by PTX.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9435681     DOI: 10.1152/ajprenal.1997.273.6.F925

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  15 in total

1.  Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease.

Authors:  Nosratola D Vaziri; Kaveh Navab; Pavan Gollapudi; Hamid Moradi; Madeleine V Pahl; Cyril H Barton; Alan M Fogelman; Mohamad Navab
Journal:  J Natl Med Assoc       Date:  2011-06       Impact factor: 1.798

2.  Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression.

Authors:  Nosratola D Vaziri; Jun Yuan; Zhenmin Ni; Susanne B Nicholas; Keith C Norris
Journal:  Clin Exp Nephrol       Date:  2011-10-19       Impact factor: 2.801

Review 3.  Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease.

Authors:  Nosratola D Vaziri
Journal:  Clin Exp Nephrol       Date:  2013-08-24       Impact factor: 2.801

4.  Reduced kidney lipoprotein lipase and renal tubule triglyceride accumulation in cisplatin-mediated acute kidney injury.

Authors:  Shenyang Li; Kiran Nagothu; Gouri Ranganathan; Syed M Ali; Brian Shank; Neriman Gokden; Srinivas Ayyadevara; Judit Megyesi; Gunilla Olivecrona; Sumant S Chugh; Sander Kersten; Didier Portilla
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-23

Review 5.  Statins in the management of dyslipidemia associated with chronic kidney disease.

Authors:  Murray Epstein; Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

Review 6.  Dyslipidemia in patients with chronic kidney disease.

Authors:  Matthew R Hager; Archana D Narla; Lisa R Tannock
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

Review 7.  HDL metabolism and activity in chronic kidney disease.

Authors:  Nosratola D Vaziri; Mohamad Navab; Alan M Fogelman
Journal:  Nat Rev Nephrol       Date:  2010-03-23       Impact factor: 28.314

8.  Impact of dyslipidemia on estimated glomerular filtration rate in apparently healthy children and adolescents: the CASPIAN-V study.

Authors:  Mohammad Moafi; Farahnak Assadi; Ramin Heshmat; Mehri Khoshhali; Mostafa Qorbani; Mohammad E Motlagh; Razieh Dashti; Majzoubeh Taheri; Roya Kelishadi
Journal:  World J Pediatr       Date:  2019-06-25       Impact factor: 2.764

Review 9.  Causes of dysregulation of lipid metabolism in chronic renal failure.

Authors:  Nosratola D Vaziri
Journal:  Semin Dial       Date:  2009 Nov-Dec       Impact factor: 3.455

Review 10.  Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.

Authors:  Nosratola D Vaziri; Keith C Norris
Journal:  Blood Purif       Date:  2013-01-22       Impact factor: 2.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.